The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol
Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., has announced results from a recent online survey of 200 radiology professionals, uncovering perspectives and expectations, with a focus on MRI contrast agents.
Bracco Diagnostics Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved Gadopiclenol Injection, a new, highly stable macrocyclic gadolinium-based contrast agent (GBCA). The introduction of VUEWAY injection is the result of a strategic, global collaboration between Bracco and Guerbet in both research, development, and manufacturing of the product signed in December 2021.
As the company celebrates its 95th anniversary, the “Bracco Fellowships” initiative will continue this year with 95 new grants for the ongoing education of young radiologists.
Bracco Renews Fellowships Initiative to Support Young Radiologists itnonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itnonline.com Daily Mail and Mail on Sunday newspapers.